AION Labs, a consortium formed by Pfizer, Merck, AstraZeneca, Teva and others, sets up company to build a computational platform to design live-saving antibodies from scratch
DenovAI is approved by the Israel Innovation Authority and will receive a $2 million grant from AION Labs and its investment partners Pfizer, AstraZeneca, Merck, Teva and Israel Biotech Fund.